Read the latest positive news, breakthroughs, and inspiring stories about semaglutide, curated daily by BrightWire.
Popular GLP-1 medications like Ozempic and Wegovy are delivering surprising health wins that kick in even before patients lose weight. From protecting hearts to easing joint pain, these drugs are proving to be more powerful than researchers initially expected.
A groundbreaking study shows that semaglutide, the medication in Wegovy and Ozempic, extended the lifespan of older mice by 12 percent while boosting memory and physical health. Scientists believe they may have found a drug that delivers the longevity benefits of calorie restriction without the hunger.
A daily pill form of semaglutide (the drug in Ozempic) helped people with alcohol use disorder drink less heavily in a University of Colorado trial. The breakthrough suggests these medications could offer new hope for treating addiction beyond their current uses.
Brazil just approved a new semaglutide treatment that could help 16.5 million people with diabetes access life-changing medication. The affordable option launches later this year, with the potential to reach millions who currently go undiagnosed or untreated.
A major new study brings surprising good news for people taking the diabetes medication semaglutide (Ozempic). Despite losing more weight than users of other medications, they experienced 15% fewer bone fractures.
Millions who avoid needles can now access a breakthrough weight loss medication in pill form. The FDA just approved oral semaglutide and a higher-dose option, making effective obesity treatment easier than ever.
A diabetes medication known for weight loss is proving to be a powerful ally for kidney and heart health. New research shows semaglutide can slow kidney disease progression and save lives.
Semaglutide, the active ingredient in Ozempic and Wegovy, helped people with obesity reduce heavy drinking days by 41% in a groundbreaking six-month trial. This marks the first randomized study testing GLP-1 drugs for alcohol use disorder treatment.
A breakthrough study of 95,000 patients found that semaglutide, the active ingredient in Ozempic and Wegovy, significantly reduces the risk of worsening mental health in people with diabetes and depression. The discovery could offer hope for millions living with both conditions.
More people with obesity are getting treatment now than at any point in the past 20 years, thanks to breakthrough medications like semaglutide. A major study tracking over 200,000 patients shows how policy changes and new drugs transformed access to life-changing care.